Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 3, 2003, Pages 105-114

  Tsujikawa, Kenji ^a   Dan, Yukihiko ^b   Nogawa, Kiyoko ^a   Sato, Hitoshi ^c   Yamada, Yasuhiko ^a   Murakami, Hideyasu ^b   Ohtani, Hisakazu ^b   Sawada, Yasufumi ^b   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

Catalepsy; Cyclosporin A; Domperidone; Dopamine receptor; Receptor occupancies

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CYCLOSPORIN A; DEXAMETHASONE; DOMPERIDONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOXORUBICIN; GLYCOPROTEIN P; HALOPERIDOL; LOPERAMIDE; METOCLOPRAMIDE; MUSCARINIC RECEPTOR; QUINIDINE; SULPIRIDE; VERAPAMIL; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN PERFUSION; CALCULATION; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG POTENTIATION; EXTRAPYRAMIDAL SYMPTOM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PARKINSONISM; RANK SUM TEST; RECEPTOR BINDING;

ANIMALS; CATALEPSY; CYCLOSPORINE; DOMPERIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MICE; P-GLYCOPROTEIN; PROTEIN BINDING; RECEPTORS, DOPAMINE; RECEPTORS, MUSCARINIC;

EID: 0038753950     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.343     Document Type: Article

References (23)

1. Farde L, Nordstöm A-L, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side-effects. Arch Gen Psychiatry 1992; 49: 538-544.
2. Farde L, Nordström A-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 1992; 160 (suppl 17): 30-33.
3. Gershanik OS. Drug-induced parkinsonism in the aged. Drugs Aging 1994; 5: 127-132.
4. Sanberg PR. Bunsey MD, Giordano M, Norman AB. The catalepsy test: its ups and downs. Behav Neurosci 1988; 102: 748-759.
5. Klemm WR. Drug effects on active immobility responses: what they tell us about neurotransmitter systems and motor functions. Prog Neurobiol 1989; 32: 403-422.
6. Haraguchi K, Ito K, Kotaki H, Sawada Y, Iga T. Prediction of drug-induced catalepsy based on dopamine D1, D2 and muscarinic acetylcholine receptor occupancies. Drug Metab Dispos 1997; 25: 675-684.
7. Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced parkinsonism. Fundam Clin Pharmacol 1994; 8: 293-306.
8. Hall H, Wedel I. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum. Acta Pharmacol Toxicol 1986; 58: 368-373.
9. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone: a review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982; 24: 360-400.
10. Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 1979; 28: 2161-2165.
11. Oliveira CR, Lima MC, Carvalhmo CA, Leysen JE, Carvalho AP. Partition coefficients of dopamine antagonists in brain membranes and liposomes. Biochem Pharmacol 1989; 38: 2113-2120.
12. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524.
13. Dan Y, Murakami H, Koyabu N, Ohtani H, Sawada Y. Distribution of domperidone into the rat brain is increased by brain ischaemia or treatment with the P-glycoprotein inhibitor verapamil. J Pharm Pharmacol 2002; 54: 729-733.
14. Sadeque AJM, Wandel C, He HB, Shah S, Wood AJJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231-237.
15. Takeguchi N, Ichimura K, Koike M, Matsui W, Kashiwagura T, Kawahara K. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. Transplantation 1993; 55: 646-650.
16. Tanaka K, Hirai M, Tanigawara Y, Yasuhara M, Hori R, Ueda K, Inui K. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Pharm Res 1996; 13: 1073-1077.
17. Fujiwara H. Comparative studies of sulpiride and classical neuroleptics on induction of catalepsy, locomotor activity and brain dopamine metabolism in mice. Pharmacol Biochem Behav 1992; 41: 301-308.
18. Asin KE, Wirtshafter D, Fibiger HC. Alterations in drug-induced catalepsy and post-decapitation convulsions following brain and spinal cord depletion of norepinephrine by the neurotoxin DSP-4. Life Sci 1982; 30: 1531-1536.
19. Yamamoto K, Hagino M, Kotaki H, Iga T. Quantitative determination of domperidone in rat plasma by high-performance liquid chromatography with fluorescent detection. J Chromatogr B 1998; 720: 251-255.
20. Murakami H, Takanaga H, Matsuo H, Ohtani H, Sawada Y. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique. Am J Physiol 2000; 279: H1022-H1028.
21. Matsui A, Matsuo H, Takanaga H, Sasaki S, Maeda M, Sawada Y. Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. J Pharmacol Exp Ther 1998; 287: 725-732.
22. Sonneveld P, Durie BG, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255-259.
23. Follath F, Wenk M, Vozeh S, Thiel G, Brunner F, Loertscher R, Lemaire M, Nusshaumer K, Niederberger W, Wood A. Intravenous cyclosporine kinetics in renal failure. Clin Pharmacol Ther 1983; 34: 638-643.